|THC||gvhd in mice via model||Targeting cannabinoid receptors as a novel approach in the treatment of graft-versus-host disease: evidence from an experimental murine model.||Sep 2011|
|Impaired hematopoiesis seen during GVHD was rescued by treatment with THC. Our results demonstrate for the first time that targeting cannabinoid receptors may constitute a novel treatment modality against acute GVHD.|
|CBD||gvhd in humans via trial (n=48)||Cannabidiol for the Prevention of Graft-versus-Host-Disease after Allogeneic Hematopoietic Cell Transplantation: Results of a Phase II Study.||Oct 2015|
Ingestion Method: 300mg/day|
The combination of CBD with standard GVHD prophylaxis is a safe and promising strategy to reduce the incidence of acute GVHD. A randomized double-blind controlled study is warranted.
|THC||gvhd in mice via experiment||d9-Tetrahydrocannabinol attenuates allogeneic host-versus-graft response and delays skin graft rejection through activation of cannabinoid receptor 1 and induction of myeloid-derived suppressor cells.||Sep 2015|
|THC treatment significantly reduced T cell proliferation and activation in draining LNs of the recipient mice and decreased early stage rejection-indicator cytokines, including IL-2 and IFN-?. THC treatment also increased the allogeneic skin graft survival.|